Phase 2 RCT in 90 patients with Behçet's syndrome and active oral ulcers: mufemilast 45 mg and 60 mg reduced the 12-week oral ulcer AUC versus placebo (differences -104.8 and -142.5, both P<.001); PDE4-related side effects were transient.
RCTn = 90
Liu et al. Efficacy and safety of mufemilast in patients with Behçet's syndrome: a phase 2 randomised clinical trial